Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Scanogen, Inc. secured a $1,000,000 NIH SBIR/STTR award: Bloodstream infection detection directly on whole blood

Sep 01, 2026•5 days ago
United States

Description

Bloodstream infection detection directly on whole blood Summary Bloodstream infection caused by yeast is a life-threatening condition that affects approximately 50,000 patients each year in the United States. Yeast bloodstream infection is a highly lethal infection associated with mortality rates greater than 40%. Early antifungal administration is crucial to improve the probability of patient survival. However, the current gold standard for the diagnosis of yeast bloodstream infection is blood

Company Information

Company

Scanogen

Location

United States

About

Scanogen Inc. is a biotechnology and medical device startup based in Baltimore, Maryland, founded in 2011. The company focuses on developing advanced molecular diagnostic platforms aimed at improving the detection of infectious diseases. With a mission to enhance healthcare, Scanogen provides rapid and ultra-sensitive diagnostic results, leveraging its collaboration with major research institutions and government agencies. The company's proprietary technology, Single MOLecule Tethering (SMOLT), allows for quick detection of biomolecules from clinical samples without traditional amplification methods. Scanogen is developing a user-friendly "sample-to-answer" diagnostic platform that includes an automated instrument and disposable cartridges. Key areas of focus include point-of-care infectious disease detection, drug resistance detection, and early cancer diagnosis. The company has received FDA Breakthrough Device Designation for its rapid bloodstream infection assay, underscoring its potential impact on patient care. Scanogen's target customers include hospitals, clinics, and specialized diagnostic laboratories, with a vision to transform the standard of care for infectious diseases and improve patient outcomes.

Predictive Intelligence
Strategic

ML-powered predictions for Scanogen's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Scanogen signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.